224 results on '"Zappe, Dion"'
Search Results
2. ZILEBESIRAN AS ADD-ON THERAPY IN PATIENTS WITH HYPERTENSION INADEQUATELY CONTROLLED WITH A STANDARD ANTIHYPERTENSIVE MEDICATION: EFFICACY AND SAFETY RESULTS FROM THE KARDIA-2 STUDY
3. The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study
4. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial.
5. Abstract 116: Safety And Tolerability Of Zilebesiran, An RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, In Obese Patients With Hypertension
6. Application of non-invasive central aortic pressure assessment in clinical trials: Clinical experience and value
7. A Randomized Study to Evaluate the Effect of an Inclisiran First Implementation Strategy vs Usual Care in Patients with ASCVD and Elevated Low-density Lipoprotein Cholesterol: Rationale and Design of the VICTORION-INITIATE Trial
8. Comparison of Benazepril Plus Amlodipine or Hydrochlorothiazide in High-Risk Patients With Hypertension and Coronary Artery Disease
9. Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension
10. Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study
11. Home and clinic blood pressure responses in elderly individuals with systolic hypertension
12. Usefulness of Heart Rate to Predict Cardiac Events in Treated Patients With High-Risk Systemic Hypertension
13. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial
14. Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk
15. CARDIOVASCULAR OUTCOMES AT RECOMMENDED BLOOD PRESSURE TARGETS IN MIDDLE AGED AND ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS AND HYPERTENSION
16. Antihypertensive Response to Thiazide Diuretic or Angiotensin Receptor Blocker in Elderly Hypertensives Is Not Influenced by Pretreatment Plasma Renin Activity
17. Valsartan: More Than a Decade of Experience
18. Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk
19. Cardiac output and renal function during insulin hypertension in Sprague-Dawley rats
20. Obesity and hypertension: roles of hyperinsulinemia, sympathetic nervous system and intrarenal mechanisms
21. Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension.
22. Fluid restriction prior to cycle exercise: effects on plasma volume and plasma proteins
23. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients
24. Randomized study to compare valsartan ± HCTZ versus amlodipine ± HCTZ strategies to maximize blood pressure control
25. Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study
26. Influence of Age and Race on 24-Hour Ambulatory Blood Pressure Responses to Valsartan, Hydrochlorothiazide, and Their Combination: Implications for Clinical Practice
27. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy
28. Application of non-invasive central aortic pressure assessment in clinical trials: Clinical experience and value
29. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial
30. Abstract 10123: Evidence Against the J-shaped Curve in Treated Hypertensive Patients With Increased Cardiovascular Risk: The VALUE Trial
31. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial
32. Changes in Aortic Pulse Wave Velocity in Hypertensive Postmenopausal Women: Comparison Between a Calcium Channel Blocker vs Angiotensin Receptor Blocker Regimen
33. Comment on ‘Time of administration important? Morning versus evening dosing of valsartan’
34. Time of administration important? Morning versus evening dosing of valsartan
35. Influence of Age and Race on 24-Hour Ambulatory Blood Pressure Responses to Valsartan, Hydrochlorothiazide, and Their Combination: Implications for Clinical Practice.
36. Blood pressure-lowering efficacy of LCZ696 in non-dipper patients with hypertension
37. Efficacy of LCZ696, an angiotensin receptor-neprilysin inhibitor (ARNI) in patients with stage 1-2 systolic hypertension
38. Age and the efficacy of LCZ696, an angiotensin receptor-neprilysin inhibitor (ARNI), compared to valsartan in patients with systolic hypertension
39. PW185 Efficacy of LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI), in patients with systolic hypertension
40. Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study
41. RELATIONSHIPS BETWEEN SYSTOLIC BLOOD PRESSURE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH HIGH RISK HYPERTENSION: AN ANALYSIS OF THE ACCOMPLISH TRIAL
42. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial
43. Antihypertensive and Metabolic Effects of Angiotensin Receptor Blocker/Diuretic Combination Therapy in Obese, Hypertensive African American and White Patients
44. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
45. Cardiovascular outcomes in hypertensive patients
46. Changes in Aortic Pulse Wave Velocity in Hypertensive Postmenopausal Women: Comparison Between a Calcium Channel Blocker vs Angiotensin Receptor Blocker Regimen
47. 786 SUB-GROUP ANALYSIS OF ACCELERATE SHOWS SUPERIORITYOF DE NOVO VS STEPWISE COMBINATION OF ALISKIREN AND AMLODIPINE IN PREVIOUSLY UNCONTROLLED HYPERTENSION
48. Does Response of RAS Blockade on Serum K+ Levels Influence Its Glycemic-Mitigating Response When Combined With Hydrochlorothiazide?
49. Comparative Efficacy of Aliskiren/Valsartan vs Valsartan in Nocturnal Dipper and Nondipper Hypertensive Patients: A Pooled Analysis
50. Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin–angiotensin–aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.